05-Feb-25 |
Buy |
Nicolas Loebel |
12.60p | 25,000 |
£3,150.00 |
03-Feb-25 |
Buy |
Carolyn Cross |
12.50p | 149,225 |
£18,653.13 |
31-Jan-25 |
Buy |
Carolyn Cross |
12.50p | 100,000 |
£12,500.00 |
30-Jan-25 |
Buy |
Carolyn Cross |
12.00p | 200,775 |
£24,093.00 |
30-Jan-25 |
Buy |
Carolyn Cross |
12.00p | 200,775 |
£24,093.00 |
03-Feb-25 |
Buy |
Carolyn Cross |
12.50p | 149,225 |
£18,653.13 |
31-Jan-25 |
Buy |
Carolyn Cross |
12.50p | 100,000 |
£12,500.00 |
05-Feb-25 |
Buy |
Nicolas Loebel |
12.60p | 25,000 |
£3,150.00 |
Carolyn Cross |
156,314,029 |
£24,370,778 |
Nicolas Loebel |
3,538,991 |
£551,761 |
Junaid Bajwa |
1,193,697 |
£186,108 |
Jean Duvall |
1,163,529 |
£181,405 |
Jean Charest |
353,356 |
£55,091 |
Simon Sinclair |
256,327 |
£39,964 |
Carolyn Cross |
119,258,222 |
£18,593,441 |
M&G Plc |
67,254,901 |
£10,485,650 |
hInsight-NX, LLC |
42,272,654 |
£6,590,691 |
Robert Cross |
37,772,652 |
£5,889,100 |
Albemarle Life Sciences Fund |
15,105,882 |
£2,355,144 |
CRUX Asset Management |
9,298,090 |
£1,449,657 |
Chelverton Asset Management |
7,957,311 |
£1,240,617 |
15:58 |
35,000 @ 15.56p |
14:57 |
2,243 @ 15.60p |
14:25 |
50,000 @ 15.50p |
14:11 |
3,000 @ 15.62p |
11:09 |
10,000 @ 15.65p |
Chair |
Jean Charest |
CEO |
Carolyn Cross |
Top of Page
You are here:
research